Abstract

Breast tumors from BRCA1 germ line mutation carriers typically exhibit features of the basal-like molecular subtype. However, the specific genes recurrently mutated as a consequence of BRCA1 dysfunction have not been fully elucidated. In this study, we used gene expression profiling to molecularly subtype 577 breast tumors, including 73 breast tumors from BRCA1/2 mutation carriers. Focusing on the RB1 locus, we analyzed 33 BRCA1-mutated, 36 BRCA2-mutated, and 48 non-BRCA1/2-mutated breast tumors using a custom-designed high-density oligomicroarray covering the RB1 gene. We found a strong association between the basal-like subtype and BRCA1-mutated breast tumors and the luminal B subtype and BRCA2-mutated breast tumors. RB1 was identified as a major target for genomic disruption in tumors arising in BRCA1 mutation carriers and in sporadic tumors with BRCA1 promoter methylation but rarely in other breast cancers. Homozygous deletions, intragenic breaks, or microdeletions were found in 33% of BRCA1-mutant tumors, 36% of BRCA1 promoter-methylated basal-like tumors, 13% of non-BRCA1-deficient basal-like tumors, and 3% of BRCA2-mutated tumors. In conclusion, RB1 was frequently inactivated by gross gene disruption in BRCA1 hereditary breast cancer and BRCA1-methylated sporadic basal-like breast cancer but rarely in BRCA2 hereditary breast cancer and non-BRCA1-deficient sporadic breast cancers. Together, our findings show the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1 status.

Highlights

  • Breast cancer is a vastly heterogeneous disease with respect to tumor biology and clinical course

  • BRCA2-mutated tumors were found in all subtypes, 56% of them were classified as luminal B (P 1⁄4 7 Â 10À9, Fisher exact test; Fig. 1C)

  • Studies established the fact that breast tumors from BRCA1 and BRCA2 germ line mutation carriers have distinct genomic and phenotypic characteristics [9, 21,22,23]

Read more

Summary

Introduction

Breast cancer is a vastly heterogeneous disease with respect to tumor biology and clinical course. Research over the past decades has identified numerous genetic alterations, but the driving events in breast tumor development are still not fully known. Global gene expression profiling has established molecular subtypes associated with characteristic pathologic. Authors' Affiliations: Departments of 1Oncology, 2Clinical Pathology, and 3Clinical Genetics, Clinical Sciences, 4CREATE Health Strategic Center for Translational Cancer Research, Lund University; 5Ska ne Department of Oncology, Ska ne University Hospital, Lund Sweden; 6Department of Pathology and Oncology, Landspitali University Hospital; 7Faculty of Medicine, University of Iceland, Reykjavik, Iceland; and Departments of 8Obstetrics and Gynecology and 9Pathology, Helsinki University Central Hospital, Helsinki, Finland. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call